Crescent Biopharma, Inc.

CBIO · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$24,607-$21,790-$2,344-$37,879
Dep. & Amort.$0$2$0$35,139
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$1,160
Change in WC$4,974$4,060-$3,168$2,391
Other Non-Cash$2,108-$4,433$405-$4,512
Operating Cash Flow-$17,525-$22,161-$5,106-$3,701
Investing Activities
PP&E Inv.-$586-$140$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$30
Investing Cash Flow-$586-$140$0$30
Financing Activities
Debt Repay.-$14$14$0$0
Stock Issued$0$5$0$0
Stock Repurch.$0-$177$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$1,254$145,550$0$0
Financing Cash Flow-$1,268$145,392$0$0
Forex Effect-$1$23,940$0$0
Net Chg. in Cash-$19,380$147,031-$5,106-$3,671
Supplemental Information
Beg. Cash$152,645$5,614$10,720$14,392
End Cash$133,265$152,645$5,614$10,720
Free Cash Flow-$18,111-$22,301-$5,106-$3,701